Impact Biomedical Inc. Announces Acquisition of Celios®, “Protecting People, Plants, and Animals from the World’s Most Dangerous Pathogens With Clean-Room Air Quality”
Impact BioMedical Inc. (NYSE American: IBO) has announced the acquisition of Celios®, an air purification technology company, in an all-equity transaction valued at $1.15 million. The strategic acquisition expands IBO's portfolio with patented air purification technology that delivers virtually clean room air quality.
Celios® brings design, system, and method patents with exclusivity through 2043, featuring U.S. manufactured filter technology that is both highly effective and portable. The acquisition aligns with Impact BioMedical's roll-up strategy, aiming to generate immediate revenue while maintaining their current cash position.
Impact BioMedical Inc. (NYSE American: IBO) ha annunciato l'acquisizione di Celios®, un'azienda specializzata nella tecnologia di purificazione dell'aria, in una transazione interamente in azioni del valore di 1,15 milioni di dollari. Questa acquisizione strategica amplia il portafoglio di IBO con una tecnologia di purificazione dell'aria brevettata che offre una qualità dell'aria interna praticamente pulita.
Celios® porta con sé brevetti di design, sistema e metodo con esclusività fino al 2043, caratterizzati da una tecnologia di filtri prodotta negli Stati Uniti, altamente efficace e portatile. L'acquisizione si allinea con la strategia di consolidamento di Impact BioMedical, mirata a generare entrate immediate mantenendo la loro attuale posizione di liquidità.
Impact BioMedical Inc. (NYSE American: IBO) ha anunciado la adquisición de Celios®, una empresa de tecnología de purificación del aire, en una transacción totalmente en acciones valorada en 1.15 millones de dólares. Esta adquisición estratégica amplía el portafolio de IBO con tecnología patentada de purificación del aire que ofrece una calidad del aire interior prácticamente limpia.
Celios® aporta patentes de diseño, sistema y método con exclusividad hasta 2043, destacándose por su tecnología de filtros fabricados en EE. UU., que es altamente efectiva y portátil. La adquisición se alinea con la estrategia de consolidación de Impact BioMedical, que busca generar ingresos inmediatos mientras mantiene su actual posición de liquidez.
Impact BioMedical Inc. (NYSE American: IBO)는 Celios®, 공기 정화 기술 회사의 인수를 발표했습니다. 이 거래는 115만 달러의 전액 주식 거래로 진행됩니다. 이 전략적 인수는 IBO의 포트폴리오를 확장하여 사실상 깨끗한 실내 공기 품질을 제공하는 특허 받은 공기 정화 기술을 추가합니다.
Celios®는 2043년까지 독점적인 디자인, 시스템 및 방법 특허를 보유하고 있으며, 미국에서 제조된 필터 기술을 특징으로 하여 매우 효과적이고 휴대 가능합니다. 이 인수는 Impact BioMedical의 통합 전략과 일치하며, 현재의 현금 위치를 유지하면서 즉각적인 수익을 창출하는 것을 목표로 하고 있습니다.
Impact BioMedical Inc. (NYSE American: IBO) a annoncé l'acquisition de Celios®, une entreprise de technologie de purification de l'air, dans le cadre d'une transaction entièrement en actions d'une valeur de 1,15 million de dollars. Cette acquisition stratégique élargit le portefeuille d'IBO avec une technologie de purification de l'air brevetée qui offre une qualité de l'air intérieur pratiquement propre.
Celios® apporte des brevets de conception, de système et de méthode avec exclusivité jusqu'en 2043, mettant en avant une technologie de filtres fabriqués aux États-Unis, à la fois hautement efficace et portable. L'acquisition s'inscrit dans la stratégie de consolidation d'Impact BioMedical, visant à générer des revenus immédiats tout en maintenant leur position de liquidité actuelle.
Impact BioMedical Inc. (NYSE American: IBO) hat die Übernahme von Celios®, einem Unternehmen für Luftreinigungstechnologie, in einer rein aktienbasierten Transaktion im Wert von 1,15 Millionen Dollar bekannt gegeben. Diese strategische Übernahme erweitert das Portfolio von IBO mit patentierter Luftreinigungstechnologie, die nahezu saubere Raumluftqualität liefert.
Celios® bringt Design-, System- und Verfahrenspatente mit Exklusivität bis 2043 mit, wobei die in den USA hergestellte Filtertechnologie sowohl hochwirksam als auch tragbar ist. Die Übernahme passt zur Roll-up-Strategie von Impact BioMedical, die darauf abzielt, sofortige Einnahmen zu generieren und gleichzeitig die aktuelle Liquiditätsposition aufrechtzuerhalten.
- All-equity transaction preserves cash position
- Patents secured until 2043
- Immediate revenue generation expected
- U.S. manufactured technology
- Small acquisition size ($1.15M)
- Dilutive effect from all-equity transaction
Insights
Impact Biomedical's $1.15 million all-equity acquisition of Celios represents a strategic expansion into the growing air purification market, diversifying beyond its core biotechnology focus. For a company with a
The acquisition brings two key assets: immediate revenue generation and valuable intellectual property with patent protection extending through 2043. This long-term IP protection creates a substantial competitive moat in the air purification space, which has seen accelerated growth since the pandemic heightened awareness of airborne pathogens.
While the all-equity structure preserves Impact's cash position for operations and future acquisitions, it will dilute existing shareholders. At current valuation, this likely represents approximately
The global air purifier market, valued at approximately
This acquisition aligns with broader ESG and wellness trends but raises questions about operational focus. Management must balance integrating and scaling Celios while maintaining momentum in core biotech initiatives. The transaction's success will depend on effective cross-selling opportunities and leveraging Celios' technology across Impact's existing healthcare relationships.
Celios' air purification technology represents a significant advancement in portable air quality management, likely utilizing advanced filtration mechanisms beyond standard HEPA systems. The technology's ability to deliver "virtually clean room" air quality in a portable format suggests breakthrough engineering in filter design, airflow dynamics, and energy efficiency.
The comprehensive patent protection through 2043 covering design, system, and methods creates a substantial technological moat. This extensive IP portfolio likely addresses the core challenges in air purification: capturing ultra-fine particles (<0.3 microns) including viruses, eliminating bioaerosols, and maintaining high air exchange rates without excessive noise or energy consumption.
From a technical perspective, Celios' competitive advantage likely stems from innovations in filter media composition, pleating geometry, and airflow engineering. Traditional portable purifiers struggle with the competing demands of high filtration efficiency and adequate air circulation – improvements in either dimension typically compromise the other.
The U.S. manufacturing emphasis suggests premium components and quality control, critical for healthcare applications where filtration failure could have serious consequences. This positions the technology for both consumer markets and more demanding healthcare, laboratory, and industrial environments where consistent performance is essential.
The acquisition gives Impact Biomedical opportunities to integrate this purification technology with their existing biomedical solutions, potentially creating hybrid products that address multiple health concerns simultaneously. The growing concern about airborne pathogens has transformed air purification from a niche product to essential infrastructure, particularly in healthcare settings, creating substantial market expansion potential for advanced solutions like Celios.
HOUSTON, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Impact BioMedical Inc. (NYSE American: IBO), a pioneering biotechnology company dedicated to discovering, developing, and patenting innovative healthcare solutions, today announced the acquisition of Celios®, a pioneering air purification technology company, in a strategic, all equity transaction valued at approximately
Celios® brings advanced air purification capability, featuring design, system, and method patents issued in the U.S. and other countries with exclusivity through 2043. It delivers "virtually clean room" air quality through novel U.S. manufactured filter technology, which is highly effective, yet portable with an easy-to-use design.
"The acquisition of Celios® marks a significant milestone in our strategic growth plan," said Frank D. Heuszel, CEO of Impact Biomedical. "By integrating Celios’® proven air purification technology into our portfolio, we are expanding our offerings of innovative health and wellness solutions. This transaction underscores our commitment to executing a disciplined roll-up strategy and accelerating revenue generation while maintaining a current comfortable cash position to drive growth in enterprise value.”
With the acquisition of Celios®, Impact Biomedical takes a substantial step forward in its mission to deliver best-in-class healthcare and wellness solutions. The addition of Celios technology complements Impact Biomedical’s existing suite of innovations, reinforcing its ambition in human health and wellness.
About Celios®:
Celios® is an advanced air purification technology company committed to improving indoor air quality through patented filtration solutions. Designed for efficiency and portability, Celios® systems provide industry-leading air purification that meets the highest standards of cleanliness and safety.
About Impact BioMedical Inc.:
Impact BioMedical Inc. (NYSE American: IBO) discovers, confirms, and patents unique science and technologies which can be developed into new offerings in biopharmaceuticals and consumer healthcare and wellness in collaboration with external partners through research, licensing, co-development, joint ventures, and other relationships.
Safe Harbor Disclosure:
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These statements are subject to risks and uncertainties that may cause actual results or events to differ materially from those projected. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date.
Investor Relations:
info@impactbiomedinc.com
www.impactbiomedinc.com
FAQ
What is the value of Impact BioMedical's acquisition of Celios?
How long do Celios' patents extend for IBO's air purification technology?
What type of transaction was used for IBO's Celios acquisition?
What are the key benefits of the Celios acquisition for Impact BioMedical (IBO)?
